Multivariate Analysis of Response and Survival After Treatment With Clofarabine, Cytarabine, and G-CSF Priming (GCLAC) in Relapsed/Refractory Acute Myeloid Leukemia: Comparison With Prior Experience Using Fludarabine and Cytarabine Combination Regimens -

Links shared publicly online about this topic.

677
total visits

Multivariate Analysis of Response and Survival After Treatment With Clofarabine, Cytarabine, and G-CSF Priming (GCLAC) in Relapsed/Refractory Acute Myeloid Leukemia: Comparison With Prior Experience Using Fludarabine and Cytarabine Combination Regimens -

Pamela S. Becker, MD, PhD, at University of Washington in Seattle, Wash., and colleagues conducted a study that indicated priming with clofarabine, cytarabine, and granulocyte colony-stimulating factor (G-CSF) (GCLAC) is active in relapsed and refractory acute myeloid leukemia (AML). Results of this study were presented at the 52nd American Society of Hematology Meeting and Exposition.

View full resource at oncologynurseadvisor.com

Tags: Leukemia, Acute Myelogenous Leukemia, Doctor